HK1203358A1 - Vaccination with interleukin-4 antagonists -4 - Google Patents

Vaccination with interleukin-4 antagonists -4

Info

Publication number
HK1203358A1
HK1203358A1 HK15103819.6A HK15103819A HK1203358A1 HK 1203358 A1 HK1203358 A1 HK 1203358A1 HK 15103819 A HK15103819 A HK 15103819A HK 1203358 A1 HK1203358 A1 HK 1203358A1
Authority
HK
Hong Kong
Prior art keywords
vaccination
interleukin
antagonists
Prior art date
Application number
HK15103819.6A
Other languages
English (en)
Chinese (zh)
Inventor
Ronald James Jackson
Charani Ranasinghe
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902345A external-priority patent/AU2012902345A0/en
Application filed by Univ Australian filed Critical Univ Australian
Publication of HK1203358A1 publication Critical patent/HK1203358A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK15103819.6A 2012-06-05 2015-04-20 Vaccination with interleukin-4 antagonists -4 HK1203358A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902345A AU2012902345A0 (en) 2012-06-05 Vaccination with Interleukin-4 Antagonists
PCT/AU2013/000589 WO2013181696A1 (fr) 2012-06-05 2013-06-05 Vaccination avec des antagonistes de l'interleukine-4

Publications (1)

Publication Number Publication Date
HK1203358A1 true HK1203358A1 (en) 2015-10-30

Family

ID=49711200

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103819.6A HK1203358A1 (en) 2012-06-05 2015-04-20 Vaccination with interleukin-4 antagonists -4

Country Status (15)

Country Link
US (1) US20150150963A1 (fr)
EP (2) EP3530283A1 (fr)
JP (1) JP2015520175A (fr)
KR (1) KR20150021088A (fr)
CN (1) CN104717971A (fr)
AU (1) AU2013271338B2 (fr)
BR (1) BR112014030436A2 (fr)
CA (1) CA2875683A1 (fr)
HK (1) HK1203358A1 (fr)
IL (1) IL236092A0 (fr)
IN (1) IN2014DN10408A (fr)
NZ (1) NZ702721A (fr)
SG (1) SG11201408101TA (fr)
WO (1) WO2013181696A1 (fr)
ZA (1) ZA201409076B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505554A (ja) * 2016-02-19 2019-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3282188B2 (ja) 1991-06-27 2002-05-13 日本電気株式会社 半導体メモリ装置
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP1512693B1 (fr) 1993-03-31 2008-11-19 Nippon Zeon Co., Ltd. Nouveau polypeptide, ADN codant pour le dit polypeptide, vecteur de recombinaison contenant ledite ADN, virus de recombinaison préparé en utilisant ledit vecteur et son utilistation
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CN1112943C (zh) 1994-01-21 2003-07-02 粉剂注射疫苗股份有限公司 气体驱动的基因送递装置
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US6265387B1 (en) 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP1042494A1 (fr) 1997-12-23 2000-10-11 Introgene B.V. Virus de recombinaison chimeriques faits d'un adenovirus et d'un virus adeno-associe utiles pour l'integration d'informations genetiques etrangeres dans l'adn chromosomique de cellules cibles
US6972013B1 (en) 1998-07-13 2005-12-06 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7608273B2 (en) 1998-08-12 2009-10-27 University Of Western Ontario Recombinant lentivirus encoding modified GP 120 signal sequences
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
EP1849873B1 (fr) 1999-04-29 2011-10-12 Gbp Ip, Llc Procédé et supports de production de vecteurs de lentivirus recombinant sécurisé à fort dosage
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
WO2001083797A2 (fr) 2000-04-28 2001-11-08 Avigen, Inc. Polynucleotides utilises dans la production de virions de virus recombinants associes aux adenovirus
EA007811B1 (ru) 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
WO2004028563A1 (fr) 2002-09-27 2004-04-08 Genexine Inc. Vaccin ameliorant l'immunite protectrice vis-a-vis du virus de l'hepatite c au moyen d'adn plasmidique et d'adenovirus recombinant
WO2007121194A1 (fr) * 2006-04-10 2007-10-25 The Regents Of The University Of California Compositions immunogènes à agents pathogènes intracellulaires recombinés immunostimulants, et procédés d'utilisation
WO2006012221A2 (fr) 2004-06-25 2006-02-02 The Regents Of The University Of California Arnsi specifique de cellules cibles et ses procedes d'utilisation
WO2006135436A2 (fr) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition de l'expression genique et ses usages therapeutiques
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8048404B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
US7611690B2 (en) 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
CA2635996A1 (fr) * 2006-01-11 2007-07-19 Aerovance, Inc. Procedes et compositions pour le traitement de l'asthme chez les primates humains et non humains
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
WO2010120511A2 (fr) * 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Procédé de traitement de troubles respiratoires
WO2011003138A1 (fr) * 2009-07-06 2011-01-13 The Australian National University Compositions immunorégulatrices comportant des inhibiteurs de l'interleukine 13 et leurs utilisations

Also Published As

Publication number Publication date
EP2854837A1 (fr) 2015-04-08
SG11201408101TA (en) 2015-01-29
CN104717971A (zh) 2015-06-17
NZ702721A (en) 2016-11-25
AU2013271338A1 (en) 2015-01-15
KR20150021088A (ko) 2015-02-27
IL236092A0 (en) 2015-01-29
JP2015520175A (ja) 2015-07-16
EP2854837A4 (fr) 2016-06-29
EP3530283A1 (fr) 2019-08-28
BR112014030436A2 (pt) 2017-09-26
CA2875683A1 (fr) 2013-12-12
WO2013181696A1 (fr) 2013-12-12
AU2013271338B2 (en) 2018-05-24
IN2014DN10408A (fr) 2015-08-14
ZA201409076B (en) 2017-06-28
US20150150963A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
HK1207967A1 (en) Vaccine
EP2925110A4 (fr) Tête de montage de composant de circuit électronique
EP2889490A4 (fr) Soufflante
EP2901893A4 (fr) Appui-tête
EP2876161A4 (fr) Vaccin
GB201223386D0 (en) Vaccine
EP2901894A4 (fr) Appui-tête
IL231043A (en) vaccine
EP2925109A4 (fr) Tête de montage de composant de circuit électronique
EP2827074A4 (fr) Humidificateur
EP2902256A4 (fr) Appui-tête
EP2902255A4 (fr) Appui-tête
GB201119999D0 (en) Vaccine
EP2902254A4 (fr) Appui-tête
PL2956700T3 (pl) Kanał powietrzny
EP2763699A4 (fr) Vaccin
ZA201306245B (en) Combination vaccines
EP2827073A4 (fr) Humidificateur
EP2771453A4 (fr) Vaccins à base de diatomée
ZA201405107B (en) Mtb-c vaccine against asthma
HK1203358A1 (en) Vaccination with interleukin-4 antagonists -4
EP2839986A4 (fr) Appuie-tête
GB201120000D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
AU2012902345A0 (en) Vaccination with Interleukin-4 Antagonists